Abstract
Charcot or neuropathic arthropathies are a progressive form of destructive, erosive and generally painless arthropathies. Prevalence of neuropathic joints has decreased globally with reduction in the cases of leprosy and syphilis. However, syringomyelia and DM have emerged as the major causes for upper limb and lower limb Charcot joints respectively. Literature evidence shows lack of India data pertaining to these arthropathies. The present study describes a case of polyarticular Charcot in a patient with syrinx and Chiari malformation. The patient history revealed a provisional diagnosis of rheumatoid arthritis and Koch’s elbow, and was treated with anti-tubercular treatment (ATT) and disease modifying anti-rheumatic drugs (DMARDS). Nervous system examination would have easily led to the diagnosis of syringomyelia. The present study also provides a review of Indian literature on neuropathic joints from 2001 to 2019. Diabetes mellitus (DM), syringomyelia, leprosy and syphilis are major etiologies for Charcot joints.
Highlights
Introductıon Neuropathic arthropathy is a destructive form of progressive articular disease
The present study discusses a rare case of polyarticular Charcot, which was provisionally diagnosed as rheumatoid arthritis, and the patient had undergone treatment with DMARDs and anti-tubercular therapy
The diagnosis of neuropathic joint is uncommon in day-today clinical practice, except in diabetes Charcot arthropathy
Summary
Neuropathic arthropathy is a minimally painful, destructive and progressive, arthropathy caused by a neurologic deficit. The mean age was 63 ± 8.36 years, and mean duration to develop neuropathic joints in DM was 18.01 ± 8.23 years.[7] Many surgical techniques and medical management were evaluated for usefulness in DM Charcot joint patients in India.[9, 16, 20] One Indian study by Durgia et al reviewed bisphosphonates, calcitonin, and denosumab in management of acute Charcot arthropathies.[41] A systemic review by Richard et al showed the effectiveness of bisphosphates in the management of acute Charcot joints, but the evidence was not strong due to insufficient data.[42] there is no study on the use of bisphosphonates for treating Charcot joint associated with non-diabetic causes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Internet Journal of Rheumatology and Clinical Immunology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
